Pieris Pharmaceuticals In... (PIRS)
NASDAQ: PIRS
· Real-Time Price · USD
13.60
-2.51 (-15.58%)
At close: Dec 13, 2024, 10:00 PM
Pieris Pharmaceuticals Revenue Breakdown
| Period Ending | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|
| Collaboration Revenue Revenue | 361K | 316K | 4.38M |
| Collaboration Revenue Revenue Growth | +14.24% | -92.78% | n/a |
| Customer Revenue Revenue | 2.58M | 10.93M | 8.88M |
| Customer Revenue Revenue Growth | -76.41% | +23.02% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 4.13M | 3.8M | 5.2M | 3.58M | 3.43M | 4.14M | 2.33M | 6.84M | 3.66M | 4.02M | 3.98M | 3.95M | 4.08M | 4.38M | 4.08M | 4.13M | 4.25M | 4.13M | 3.67M | 4.12M | 4.57M | 4.36M | 4.48M | 4.83M | 4.19M | 4.93M | 4.56M | 4.75M | 4.78M | 4.35M | 6.39M | 2.85M | 4.35M | 3.99M | 2.21M | 2.34M | 2.37M | 1.97M | 1.76M | 2.24M | 1.97M | 2.39M |
| Selling, General, and Administrative Revenue Growth | +8.82% | -26.99% | +45.24% | +4.52% | -17.21% | +77.83% | -65.97% | +86.65% | -8.92% | +0.95% | +0.91% | -3.23% | -6.81% | +7.20% | -1.14% | -2.68% | +2.81% | +12.53% | -10.84% | -9.89% | +4.79% | -2.79% | -7.26% | +15.42% | -15.06% | +8.06% | -3.88% | -0.65% | +9.81% | -31.94% | +124.17% | -34.41% | +9.02% | +80.18% | -5.44% | -1.15% | +20.34% | +11.68% | -21.44% | +13.90% | -17.76% | n/a |
| Research and Development Revenue | 5.12M | 4.07M | 6.6M | -446K | 751K | 1.25M | 4.45M | 9.6M | 14.33M | 13.42M | 13.38M | 13.59M | 11.95M | 14.07M | 15.36M | 18.94M | 15.8M | 16.56M | 10.62M | 11.82M | 11.33M | 12.76M | 14.12M | 13.21M | 13.37M | 14.3M | 13M | 11.4M | 9.15M | 7.94M | 5.27M | 6.26M | 5.4M | 5.36M | 6.92M | 4.62M | 4.5M | 3.66M | 2.94M | 2.05M | 1.73M | 1.52M |
| Research and Development Revenue Growth | +25.63% | -38.25% | -1579.37% | -159.39% | -39.82% | -71.98% | -53.58% | -33.03% | +6.73% | +0.33% | -1.54% | +13.74% | -15.06% | -8.41% | -18.90% | +19.85% | -4.60% | +55.98% | -10.18% | +4.31% | -11.17% | -9.62% | +6.85% | -1.21% | -6.46% | +9.99% | +14.01% | +24.53% | +15.36% | +50.59% | -15.80% | +16.00% | +0.67% | -22.51% | +49.66% | +2.71% | +22.97% | +24.35% | +43.44% | +18.90% | +13.18% | n/a |